List of Excipients in Branded Drug ASENAPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	ASENAPINE	asenapine maleate	59762-1091	GELATIN
Greenstone LLC	ASENAPINE	asenapine maleate	59762-1091	MANNITOL
Greenstone LLC	ASENAPINE	asenapine maleate	59762-1091	SUCRALOSE

Generic Drugs Containing ASENAPINE

Company	Ingredient	NDC	Excipient
Sigmapharm Laboratories LLC	asenapine	42794-016	ANHYDROUS CITRIC ACID
Sigmapharm Laboratories LLC	asenapine	42794-016	BUTYLATED HYDROXYTOLUENE
Sigmapharm Laboratories LLC	asenapine	42794-016	COPOVIDONE
Sigmapharm Laboratories LLC	asenapine	42794-016	CROSPOVIDONE
Sigmapharm Laboratories LLC	asenapine	42794-016	MAGNESIUM STEARATE
Sigmapharm Laboratories LLC	asenapine	42794-016	MALTODEXTRIN

What are the Most Frequently-Used Excipients in ASENAPINE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
3	ASPARTAME
4	BUTYLATED HYDROXYANISOLE
5	BUTYLATED HYDROXYTOLUENE
3	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE

Excipient Strategy and Commercial Opportunities for ASENAPINE

Last updated: February 28, 2026

What are the current excipient strategies for ASENAPINE formulations?

ASENAPINE is marketed primarily as a sublingual tablet for schizophrenia and bipolar disorder. The excipient strategy focuses on optimizing bioavailability, stability, and patient compliance.

Formulation overview

• Active Ingredient: ASENAPINE maleate
• Delivery Route: Sublingual
• Approaches: Use of mucoadhesive agents, flavoring agents, and disintegrants

Common excipients

• Sublingual tablet composition typically includes:
  • Disintegrants: Crospovidone or croscarmellose sodium for rapid dissolution
  • Mucoadhesive agents: Hydroxypropyl methylcellulose (HPMC) to enhance contact time
  • Flavoring agents: Mint or menthol to improve palatability
  • Sweeteners: Sucralose or aspartame to mask bitterness
  • Lubricants: Magnesium stearate to facilitate manufacturing

Customization strategies

• Bioavailability enhancement: Incorporation of permeability enhancers such as chitosan
• Stability improvements: Use of antioxidants within excipient blends
• Patient compliance: Flavor modifications and rapid disintegration properties

What are the commercial opportunities associated with excipient innovations?

Market growth potential

• The global antipsychotic drugs market was valued at approximately USD 12 billion in 2021, with ASENAPINE accounting for a significant share due to its unique sublingual administration.
• The rising prevalence of schizophrenia and bipolar disorder increases demand for formulations that improve adherence.

Opportunities for excipient innovation

• Enhanced bioavailability: Developing proprietary permeability enhancers can lead to more effective formulations with lower dosages.
• Taste masking: Advanced flavoring and coating technologies can improve patient tolerability, especially critical for pediatric and geriatric populations.
• Extended shelf life: Incorporating antioxidants and stabilizers into excipients extends product shelf life, providing logistical advantages.

Strategic markets

• Emerging markets: Growing mental health awareness coupled with approve generics provides opportunities for branded excipient formulations.
• Regulatory trends: Favoring excipients on the Generally Recognized as Safe (GRAS) list accelerates approval paths.
• Innovation incentives: Patent extensions and exclusivity periods tied to formulation improvements create lucrative pathways.

Partnerships and licensing

• Opportunities exist for pharmaceutical companies to license innovative excipient technologies from specialized suppliers, reducing R&D costs while entering new markets.

How does the regulatory landscape influence excipient choices for ASENAPINE?

• Regulatory standards: The FDA and EMA require detailed excipient safety profiles, especially for sublingual formulations.
• Novel excipient approval: New excipients must undergo rigorous safety assessments; thus, using established excipients limits regulatory hurdles.
• Labeling considerations: Clear disclosure of excipient ingredients supports compliance and enhances consumer trust.

Comparative perspective on excipient strategies across drugs

Aspect	ASENAPINE	Other Sublingual Drugs
Disintegrant type	Crospovidone, croscarmellose sodium	Microcrystalline cellulose, starch
Flavoring agents	Mint, menthol	Fruit flavors, vanilla
Mucoadhesives	HPMC, Carbopol	Pectin, chitosan
Sweeteners	Sucralose, aspartame	Saccharin, stevia

Key Takeaways

• ASENAPINE formulations leverage excipients that promote rapid disintegration, flavor masking, and stability.
• Innovation in bioavailability enhancers and taste modifiers presents market differentiation.
• Regulatory considerations favor excipients with established safety profiles.
• Partnerships and licensing enable accelerated market entry and cost reduction.
• The expanding mental health market and favorable regulatory climate create lucrative opportunities for excipient innovation.

FAQs

1. What excipients are essential for ASENAPINE sublingual tablets?
Disintegrants (crospovidone), mucoadhesives (HPMC), flavoring agents (menthol), sweeteners (sucralose), and lubricants (magnesium stearate).

2. How can excipient innovation improve ASENAPINE’s marketability?
By enhancing bioavailability, taste, stability, and manufacturing efficiency, excipient innovation can differentiate products and improve patient compliance.

3. Are there regulatory restrictions on excipients used in ASENAPINE formulations?
Yes. Excipients must meet safety standards set by agencies like FDA and EMA, favoring those with proven safety profiles.

4. What emerging markets present the most opportunity for ASENAPINE excipient strategies?
Emerging markets with increasing mental health awareness and expanding healthcare infrastructure, such as India, China, and Brazil.

5. How does the choice of excipients impact patentability and exclusivity?
Formulation-specific excipient combinations can qualify for new patents, extending market exclusivity.

---

References

[1] Grand View Research. (2022). Antipsychotic Drugs Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2021). Inactive Ingredients Database.
[3] EMA. (2021). Guideline on Excipients in the Labeling and Packaging of Medicinal Products for Human Use.